Traduction de «effectiveness level » (Anglais → Français) :

no-observed-adverse-effect level [ NOAEL | no observed adverse effect level | no-observed-adverse-effect-level ]

lowest-observed-adverse-effect level [ LOAEL | lowest observed adverse effect level | lowest-observed-adverse-effect-level ]

no effect level | no-effect level | NEL [Abbr.]

no observable adverse effect level | no-observed-adverse-effect level | NOAEL [Abbr.]

levelling effect [ leveling effect ]

no-observed-effect level

no-observed-adverse-effect level

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

e) taking steps to promote international dialogue and co-operation with a view to work towards a level playing field with industrialised countries in patent protection on biotechnology inventions, ensuring an effective level of protection for innovation in this field.

to consolidate progress towards an integrated, open, competitive, and economically efficient European financial market and to remove the remaining economically significant barriers; to foster a market where financial services and capital can circulate freely at the lowest possible cost throughout the EU - with adequate and effective levels of prudential control, financial stability and a high level of consumer protection; to implement, enforce and continuously evaluate the existing legislative framework, to deploy rigorously the better regulation agenda for any future initiatives, to enhance su ...[+++]pervisory convergence and strengthen European influence in global financial markets.

Applying an uncertainty factor of 100 to the No Observed Adverse Effect Level (NOAEL) of 20 μg/kg bodyweight (b.w.) per day results in a level of no concern for nephrotoxicity in humans of 0,2 μg/kg b.w. per day.

The data derived from these tests should allow the determination of No-Observed Adverse Effect Levels (NOAELs), Lowest Observed Adverse Effect Levels (LOAELs) and/or benchmark doses for the various endpoints and/or be used to characterise effects detected in previous repeat-dose studies and/or serve as a guide for subsequent testing.